News

HESylation® - News


Fresenius Kabi and Boehringer Ingelheim RCV successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi’s HESylation® Technology



Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation® Technology



Fresenius Kabi and Octapharma Group enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein



Fresenius Kabi and Bayer Schering Pharma enter into a Research, Development and License Agreement regarding HESylation® Technology